anti pher2  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti pher2
    Anti Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    anti pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti pher2
    Anti Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Merck KGaA anti pher2
    Anti Pher2, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pher2/product/Merck KGaA
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc pher2
    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of <t>pHER2,</t> HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors"

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    Journal: Chinese Journal of Cancer Research

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Figure Legend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

    Techniques Used: Western Blot

    Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.
    Figure Legend Snippet: Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Techniques Used: Migration, Wound Healing Assay, Western Blot

    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.
    Figure Legend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Techniques Used: Immunohistochemistry

    pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc pher2
    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of <t>pHER2,</t> HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors"

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    Journal: Chinese Journal of Cancer Research

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Figure Legend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

    Techniques Used: Western Blot

    Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.
    Figure Legend Snippet: Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Techniques Used: Migration, Wound Healing Assay, Western Blot

    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.
    Figure Legend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Techniques Used: Western Blot

    Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.
    Figure Legend Snippet: Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Techniques Used: Immunohistochemistry

    pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc pher2
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc pher2
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Santa Cruz Biotechnology pher2
    Pher2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Santa Cruz Biotechnology pher2
    Pher2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    pher2  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc pher2
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc anti pher2
    Anti Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pher2 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Merck KGaA anti pher2
    Anti Pher2, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pher2/product/Merck KGaA
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pher2 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc pher2
    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of <t>pHER2,</t> HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Pher2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology pher2
    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of <t>pHER2,</t> HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
    Pher2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-sensitive HER2+ breast cancer cells. (A,B) SK-BR-3 (A) and BT-474 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) SK-BR-3 (C) and BT-474 (D) cells were treated with PYR for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Western Blot

    Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib inhibits proliferation, migration, invasion, and HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A) Dose-response curves of HCC1569 and HCC1954 cells after 3 d of treatment with PYR. IC50 values were determined after 3 d of treatment with PYR; (B−E) Colony formation assays in HCC1569 (B,C) and HCC1954 (D,E) cells treated with CTRL, trastuzumab (TRA, 10 µg/mL), PYR (100 nmol/L), or TRA+PYR. Relative number of colonies (normalized to CTRL) was quantified using ImageJ; (F) Wound healing assay for HCC1954 cells treated with CTRL, TRA, PYR, and TRA+PYR. Images were taken at 0, 24, and 48 h; (G,H) Migration (G) and invasion (H) of HCC1954 cells were evaluated by transwell assays without or with matrigel-coated insert; (I−L) HCC1569 (I,K) and HCC1954 (J,L) cells were treated with increasing concentrations of PYR for 24 h or indicated times with PYR. The levels of indicated protein were assessed by western blot; (M,N) HCC1569 (M) and HCC1954 (N) cells were treated with TRA for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S2. TRA, trastuzumab; PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Migration, Wound Healing Assay, Western Blot

    Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib inhibits HER2 downstream pathways in trastuzumab-resistant HER2+ breast cancer cells. (A,B) HCC1569 (A) and HCC1954 (B) cells were treated with increasing concentrations of PYR for 24 h; (C,D) HCC1569 (C) and HCC1954 (D) cells were treated with PYR for the indicated times; (E,F) HCC1569 (E) and HCC1954 (F) cells were treated with TRA for the indicated times. All the levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. PYR, pyrotinib; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01; ***, P<0.001.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib is superior to pertuzumab in inhibiting proliferation and HER2 downstream pathway in HER2+ breast cancer cells. (A−D) SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cell lines were treated with TRA, TRA+PYR, or TRA+ PER at the indicated concentrations for 3 d. Proliferation of breast cancer cells was analyzed and normalized to CTRL (%); (E−H) SK-BR-3 (E), BT-474 (F), HCC1569 (G), and HCC1954 (H) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown in Supplementary Figure S3. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. ***, P<0.001; ****, P<0.0001.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Western Blot

    Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib is superior to pertuzumab in inhibiting HER2 downstream pathways in HER2+ breast cancer cells. SK-BR-3 (A), BT-474 (B), HCC1569 (C), and HCC1954 (D) cells were treated with CTRL, TRA (10 µg/mL) combined with PYR (100 nmol/L) or PER (10 µg/mL) for the indicated times. The levels of pHER2, HER2, pAKT, AKT, pERK, ERK, and GAPDH were assessed by western blot. The quantifications of blots are shown above. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Western Blot

    Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Journal: Chinese Journal of Cancer Research

    Article Title: Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors

    doi: 10.21147/j.issn.1000-9604.2024.02.03

    Figure Lengend Snippet: Pyrotinib is superior to pertuzumab in suppressing tumor growth in a xenograft model. (A) HCC1954 xenograft mouse model was treated with CTRL, TRA, PYR, TRA+PYR, or TRA+PER for 24 d. The black arrow indicates the initial time of treatment. Tumor volume was measured twice a week, and data are presented as ; (B) After 24 d of treatment, mice were sacrificed, and tumors were dissected and photographed; (C) Body weight of mice was measured twice a week; data are presented as ; (D) IHC staining was performed for pHER2, pAKT, pERK, and Ki-67 in paraffin sections of HCC1954 xenograft tumors; (E) IHC scores were quantified and presented. n=6/group. TRA, trastuzumab; PYR, pyrotinib; PER, pertuzumab; HER2, human epidermal growth factor receptor 2. *, P<0.05; **, P<0.01.

    Article Snippet: Briefly, tumor tissue sections were deparaffinized, rehydrated, and boiled in a pressure cooker with repair solution for antigen retrieval for 2.5 min. After treatment with endogenous peroxidase blocker for 10 min, sections were incubated with normal goat serum blocking solution (ZSGB-BIO) for 1 h and then incubated with primary antibodies at 4 °C overnight or at room temperature for 1 h. The primary antibodies are as follows: pHER2 (Cell Signaling Technology, Cat#2243S), pAKT (Cell Signaling Technology, Cat#3787S), pERK (Cell Signaling Technology, Cat#4370S), and Ki-67 (Cell Signaling Technology, Cat#9449T).

    Techniques: Immunohistochemistry